Bitcoin price today: slips below $113k, near 6-wk low despite Fed cut bets
ALISO VIEJO, California - RxSight, Inc. (NASDAQ:RXST) saw its shares surge 4.9% after the ophthalmic medical device company reported better-than-expected fourth quarter earnings and reaffirmed strong guidance for 2025.
The company, which specializes in customized vision solutions for cataract surgery patients, posted adjusted earnings per share of $0.03 for Q4 2024, beating analyst estimates of a $0.17 loss. Revenue came in at $40.2 million, slightly below the consensus of $40.39 million but up 41% YoY.
RxSight’s Q4 performance was driven by a 61% increase in Light Adjustable Lens (LAL) procedure volume and a 46% expansion of its Light Delivery Device (LDD) installed base compared to the same quarter last year.
For the full year 2024, RxSight reported revenue of $139.9 million, a 57% increase over 2023. The company reaffirmed its 2025 revenue guidance of $185.0 million to $197.0 million, representing growth of 32% to 41% compared to 2024. This outlook aligns with analyst expectations of $189.33 million.
"The progress we’ve made over the past year has strengthened our conviction that adjustability has the potential to transform the premium cataract market," said Dr. Ron Kurtz, CEO and President of RxSight.
The company’s gross profit margin improved to 71.6% in Q4 2024, up from 61.8% in Q4 2023, reflecting a favorable product mix and lower costs.
RxSight ended the year with a strong balance sheet, reporting $237.2 million in cash, cash equivalents, and short-term investments as of December 31, 2024.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.